Industry context
Predictive Oncology Inc [POAI]
Last Updated 21 Apr 2026 @ 15:59 (Exchange is closed)
Last: $4.91
6.28%
-2.04 (↓)
GaG Algo Score™
v1.0
Short
-2.04 (↓)
Medium
-1.47 (↓)
Long
-1.81 (↓)
Line
Pivot Data
Pivot Statistics
Insufficient pivot data for statistics.
Next Pivot Prediction Last: $4.91
Unable to generate prediction based on available data.
Predictive Oncology Inc plummets -20.00%.
Predictive Oncology Inc (POAI) stock price recorded a historic drop on Monday after the stock fell $-1.170 (-20.00%) from the previous session on normal volume. The stock fell slightly more than the NASDAQ which was down -0.43%. With 441 020 shares traded, volume yesterday reached $2.06M. This was 95 188 shares more than the prior day. Compared to the 10-day average of 361 552 shares, volume was more than the average.
Predictive Oncology Inc signals
There is no conclusive signals given from RSI. The price is below both moving averages, but the short-term average has crossed above the long-term average, suggesting a possible shift toward an up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-16.7%), medium- (-16.7%), and long-term (-16.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Predictive Oncology Inc Support & Resistance Levels
The stock is approaching the closest resistance level at $4.76. approximately $0.0800 (1.71%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $7.1. On a fall back there will be support at $4.07 The dis das resistance s14.07 -
Predictive Oncology Inc Evaluation
- Short score: -2.04
- Medium score: -1.47
- Long score: -1.81
Ownership flow
GetAGraph InsiderPower
Transactions
23
Buy power
18.77M
Sell power
0
Reliability
100/100
Buy / sell
999.00
Hist. corr.
0.53
Latest signal
Buy 2025-09-24
Director 14
Officer 9
2026-05-14
Blacher Joshua Officer
Buy 9 389
2026-05-14
Blacher Joshua Officer
Buy 9 389
2025-11-28
Vennare Raymond F Officer
Other 2 373
2025-10-08
Mclaughlin Thomas Louis Officer
Other
2025-10-08
Mclaughlin Thomas Louis Officer
Other
2025-10-07
Matthews Shawn Director
Other
Relationship map
Correlation snapshot
Positioning pressure
Short interest pressure
Short interest
9.47%
Of outstanding shares
Short float
9.55%
Of tradable float
Days to cover
3.20
Short interest divided by average volume
Squeeze probability
11.00%
-9.66% change
Short positioning does not currently stand out as a dominant risk factor.
Updated 2025-11-28Earnings quality
Earnings history
Reported quarters
10
EPS beats
0
EPS misses
4
Avg. surprise
-935.35%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-10 | - | - | - | - |
| Q2/2025 | 2025-08-12 | - | $-0.0900 | - | - |
| Q1/2025 | 2025-05-14 | $-0.320 | $-0.0900 | -255.56% | 110 310 |
| Q4/2024 | 2025-03-27 | $-0.850 | $-0.250 | -240.00% | 611 585 |
| Q3/2024 | 2024-11-12 | $-0.360 | $-0.320 | -12.50% | 345 686 |
| Q2/2024 | 2024-08-13 | $-0.680 | - | - | 278 722 |
| Q1/2024 | 2024-05-14 | $-1.040 | - | - | 419 646 |
| Q4/2023 | 2024-03-28 | $-0.850 | - | - | 335 032 |
News flow
Latest company news
Market coverage
defenseworld.net Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened Apr 21, 2026 defenseworld.net Predictive Oncology Q4 Earnings Call Highlights Apr 3, 2026 defenseworld.net Predictive Oncology (NASDAQ:POAI) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened Mar 19, 2026 defenseworld.net Predictive Oncology (NASDAQ:POAI) versus Mitesco (OTCMKTS:MITI) Head-To-Head Comparison Feb 10, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical Instruments Supplies
Currency
USD
Predictive Oncology Inc a knowledgedriven company focuses on developing personalized cancer therapies using artificial intelligence AI primarily in the United States The company operates in four segments Helomics zPREDICTA Soluble and Skyline The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests and contract research services through patientcentric drug discovery using active learning technology for discovery clinical and translational research clinical trials and diagnostic development and validation The zPREDICTA segment develops organspecific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents The Soluble segment provides services using HighThroughput SelfInteraction Chromatography a selfcontained automated system that conducts highthroughput selfinteraction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics This segment also offers protein stability analysis services protein solubility kits that allow rapid identification of soluble formulations and proprietary technologies for bacterial endotoxin detection and removal The Skyline segment provides STREAMWAY System a wallmounted fully automated system which virtually eliminates staff exposure to blood irrigation fluid and other infectious fluids found in the healthcare environment It also offers research and development services and media that help cancer cells grow outside the patients body and retain their DNARNA and proteomic signatures The company was formerly known as Precision Therapeutics Inc and changed its name to Predictive Oncology Inc in June 2019 Predictive Oncology Inc was incorporated in 2002 and is based in Eagan Minnesota
Navigation